Optimal blood pressure for patients with chronic kidney disease: a nationwide population-based cohort study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, You-Bin | - |
dc.contributor.author | Lee, Ji Sung | - |
dc.contributor.author | Hong, So-hyeon | - |
dc.contributor.author | Kim, Jung A. | - |
dc.contributor.author | Roh, Eun | - |
dc.contributor.author | Yoo, Hye Jin | - |
dc.contributor.author | Baik, Sei Hyun | - |
dc.contributor.author | Choi, Kyung Mook | - |
dc.date.accessioned | 2021-08-30T04:03:42Z | - |
dc.date.available | 2021-08-30T04:03:42Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2021-01-15 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/50105 | - |
dc.description.abstract | The effect of blood pressure (BP) on the incident cardiovascular events, progression to end-stage renal disease (ESRD) and mortality were evaluated among chronic kidney disease (CKD) patients with and without antihypertensive treatment. This nationwide study used the Korean National Health Insurance Service-Health Screening Cohort data. The hazards of outcomes were analysed according to the systolic BP (SBP) or diastolic BP (DBP) among adults (aged >= 40 years) with CKD and without previous cardiovascular disease or ESRD (n=22,278). The SBP and DBP were >= 130 mmHg and >= 80 mmHg in 10,809 (48.52%) and 11,583 (51.99%) participants, respectively. During a median 6.2 years, 1271 cardiovascular events, 201 ESRD incidents, and 1061 deaths were noted. Individuals with SBP >= 130 mmHg and DBP >= 80 mmHg had higher hazards of hypertension-related adverse outcomes compared to the references (SBP 120-129 mmHg and DBP 70-79 mmHg). SBP<100 mmHg was associated with hazards of all-cause death, and composite of ESRD and all-cause death during follow-up only among the antihypertensive medication users suggesting that the BP should be<130/80 mmHg and the SBP should not be<100 mmHg with antihypertensive agents to prevent the adverse outcome risk of insufficient and excessive antihypertensive treatment in CKD patients. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | NATURE RESEARCH | - |
dc.subject | CLINICAL-PRACTICE GUIDELINE | - |
dc.subject | CARDIOVASCULAR-DISEASE | - |
dc.subject | ARTERIAL-HYPERTENSION | - |
dc.subject | MANAGEMENT | - |
dc.subject | MORTALITY | - |
dc.subject | RISK | - |
dc.subject | OUTCOMES | - |
dc.title | Optimal blood pressure for patients with chronic kidney disease: a nationwide population-based cohort study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoo, Hye Jin | - |
dc.contributor.affiliatedAuthor | Choi, Kyung Mook | - |
dc.identifier.doi | 10.1038/s41598-021-81328-y | - |
dc.identifier.scopusid | 2-s2.0-85099437775 | - |
dc.identifier.wosid | 000609782400059 | - |
dc.identifier.bibliographicCitation | SCIENTIFIC REPORTS, v.11, no.1 | - |
dc.relation.isPartOf | SCIENTIFIC REPORTS | - |
dc.citation.title | SCIENTIFIC REPORTS | - |
dc.citation.volume | 11 | - |
dc.citation.number | 1 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.subject.keywordPlus | CLINICAL-PRACTICE GUIDELINE | - |
dc.subject.keywordPlus | CARDIOVASCULAR-DISEASE | - |
dc.subject.keywordPlus | ARTERIAL-HYPERTENSION | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | OUTCOMES | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.